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Abstract  
The concentration of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) in whole blood 
is used as a parameter for assessing the consumption behavior of cannabis consumers. The 
blood level of THCCOOH-glucuronide might provide additional information about the 
frequency of cannabis use. To verify this assumption a column-switching liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method for the rapid and direct 
quantification of free and glucuronidated THCCOOH in human whole blood was newly 
developed. The method comprised protein precipitation, followed by injection of the 
processed sample onto a trapping column and subsequent gradient elution to an analytical 
column for separation and detection. The total LC run time was 4.5 min. Detection of the 
analytes was accomplished by electrospray ionization in positive ion mode and selected 
reaction monitoring using a triple stage quadrupole mass spectrometer. The method was fully 
validated by evaluating the following parameters: linearity, lower limit of quantification, 
accuracy and imprecision, selectivity, extraction efficiency, matrix effect, carry-over, dilution 
integrity, analyte stability and re-injection reproducibility. All acceptance criteria were 
analyzed and the predefined criteria met. Linearity ranged from 5.0 – 500 µg/L for both 
analytes. The method was successfully applied to whole blood samples from a large collective 
of cannabis consumers, demonstrating its applicability in the forensic field. 
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Introduction 
Cannabis is the most widely abused illicit drug worldwide [1]. Not surprisingly, roadside 
surveys have demonstrated that driving under the influence of cannabis (DUIC) is a common 
and widespread occurrence [2-5]. Cannabis consumption has been shown to have impairing 
effects on cognitive functions and psychomotor skills related to driving and to be associated 
with an elevated accident risk [6-9]. Thus, DUIC has severe implications on global road 
safety and is considered a serious criminal offense in many countries [10].  
Δ9-Tetrahydrocannabinol (THC), the major psychoactive component of cannabis, is 
extensively metabolized in humans, mainly by liver enzymes. Phase I biotransformation 
involves hydroxylation to active 11-hydroxy-THC (11-OH-THC), followed by oxidation to 
inactive 11-nor-9-carboxy-THC (THCCOOH). Further biotransformation via phase II 
glucuronidation produces hydrophilic conjugates that are easily excreted [11].  
Due to its long elimination half-life [11] , THCCOOH accumulates in the blood upon regular 
cannabis use [12-15] and has therefore been proposed as diagnostic marker to distinguish 
between occasional and heavy users [16,17]. In Switzerland, a free THCCOOH blood level of 
40 µg/L is currently used as cut-off for the classification of impaired drivers as heavy users, 
as recommended by Fabritius et al. [17,18]. Since chronic cannabis consumption may imply a 
long-term unfitness to drive, these drivers suspected of heavy cannabis misuse are required to 
undergo medical assessment of their fitness to drive, even if no active THC was detected in 
their blood. As a road safety measure, unfit drivers face a suspension of their driver’s license 
by administrative authorities. After a proven period of abstinence and regular medical check-
ups, the driver’s license may be re-issued. 
In the study conducted by Fabritius et al. [17] the 40 µg/L cut-off for free THCCOOH 
showed a low sensitivity, implying that its ability to correctly identify heavy users is rather 
poor. Since THCCOOH in blood is extensively glucuronidated [19], we hypothesize that the 
free THCCOOH blood level is not solely determined by the consumption frequency, but is 
also dependent on the individual glucuronidation rate. Indeed, several studies have shown that 
the ratio of conjugated to free THCCOOH in plasma or blood was variable between 
participants at a given time point following controlled THC administration [12,15,19,20]. In 
our view, these findings suggest that there are interindividual differences in the THCCOOH 
glucuronidation rate which could be attributed to genetic polymorphisms of  the 
glucuronosyltransferase enzymes catalyzing the glucuronidation of cannabinoids [21,22]. 
Furthermore, as reported for THCCOOH [12-15], serum, plasma and blood levels of 
THCCOOH-glucuronide have been found to be higher in heavy cannabis users than in 
occasional users [12,14,15]. Therefore, we assume that THCCOOH-glucuronide blood 
concentrations could serve as an additional marker for assessing the frequency of cannabis use 
and that the recognition of heavy users could be improved if both the free and glucuronidated 
THCCOOH blood levels are taken into account. 
Numerous analytical methods for the quantification of THC and its metabolites in biological 
fluids have been developed, which are mostly based on gas chromatography (GC) or liquid 
chromatography (LC) coupled to mass spectrometry (MS) [23,24]. However, the direct and 
simultaneous determination of THCCOOH and its glucuronide by GC-MS is not possible as 
glucuronides are thermally unstable and non-volatile [25,26]. To quantify THCCOOH-
glucuronide by GC-MS, free THCCOOH is analyzed first and then the glucuronide is 
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hydrolyzed to measure total THCCOOH. The amount of THCCOOH-glucuronide is 
calculated as the difference between total and free THCCOOH [12]. Since hydrolysis can be 
variable and/or incomplete this procedure can lead to ambiguous results [27,28]. The use of 
LC-MS/MS eliminates the need of costly and time-consuming alkaline and/ or enzymatic 
glucuronide hydrolysis, enabling direct measurement of free and glucuronidated THCCOOH. 
As native and isotopically labeled THCCOOH-glucuronide standards have become available 
only recently, few LC-MS/MS for quantifying THCCOOH-glucuronide in biological fluids 
exist [25,29-33]. Schwope et al. [25] and Gronewold et al. [31] reported the only two existing 
methods for simultaneously measuring free and glucuronidated THCCOOH in whole blood, 
along with free and glucuronidated THC, 11-OH-THC, cannabinol and cannabidiol. Sample 
preparation consisted of protein precipitation followed by solid phase extraction [25] or 
liquid-liquid extraction [31] and chromatographic separation of the analytes was 
accomplished in 16 min and 10 min, respectively.  
In this work, a validated column-switching LC-MS/MS method for the direct and 
simultaneous quantification of THCCOOH and THCCOOH-glucuronide in whole blood is 
reported. Key factors are a low sample volume, a straightforward sample preparation 
procedure and a fast chromatography. This novel high-throughput method is used to 
investigate whether THCCOOH-glucuronide whole blood concentration complements free 
THCCOOH level for assessing cannabis consumption frequency.  
 
Experimental 
Materials 
Standard solutions of THCCOOH, THCCOOH-glucuronide and their tri-deuterated analogs 
(carrying a tri-deuterated methyl group at the end of the pentyl side chain) were purchased at 
a concentration of 100 µg/mL from Cerilliant Corporation (Round Rock, TX, USA). 
Acetonitrile (HPLC gradient grade, 99.9%) was obtained from Acros Organics (Chemie 
Brunschwig, Basel, Switzerland), methanol (absolute, HPLC grade) from Biosolve (Chemie 
Brunschwig, Basel, Switzerland) and formic acid (analytical grade, 98%) was acquired from 
Fluka (Sigma-Aldrich, Buchs, Switzerland). Water was purified in-house with a Milli-Q water 
system from Millipore (Zug, Switzerland). Precision pipettes from Gilson (Mettmenstetten, 
Switzerland) were used for handling of all solutions and samples. Blank human blood was 
obtained from the blood donor center in Bern, Switzerland and was analyzed prior to its use to 
verify absence of analytes. Authentic blood samples were collected in tubes containing 
potassium fluoride as anticoagulant. Sample preparation was carried out in 96 deep well 
plates (round bottom, 1 mL) obtained from Corning (Chemie Brunschwig, Basel, 
Switzerland) and sealed with silicone mats from Axygen (Chemie Brunschwig, Basel, 
Switzerland). 
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Preparation of calibration and quality control samples 
Working solutions for preparing calibration and quality control (QC) samples were obtained 
via dilution of the reference standard solutions in methanol. Separate dilution series were used 
for the preparation of calibration and QC working solutions. All working solutions were 
stored at -20 °C in polypropylene tubes. Adding 5 µL of working solution to 95 µL of blank 
blood created calibration samples at 5, 10, 25, 50, 100, 250 and 500 µg/L and QC samples at 
5, 15, 125 and 400 µg/L. Calibration and QC samples were freshly prepared in 96 deep well 
plates on each day of analysis.  
 
Sample preparation 
Protein precipitation was performed in 96 deep well plates by adding 300 µL of cold 
acetonitrile containing the deuterated internal standards (50 µg/L THCCOOH-d3 and 20 µg/L 
THCCOOH-d3-glucuronide) to 100 µL of blood (calibration, QC or unknown sample). 
Subsequently, the well plates were sealed, vortexed for 10 min and centrifuged (Rotanta 460 
R, Hettich, Bäch, Switzerland) for 35 min at 4234 g and 4 °C. The plates were placed in the 
cooled autosampler and 40 µL of each supernatant were injected into the LC-MS/MS system. 
 
Liquid chromatography 
Chromatography equipment consisted of an UltiMate
®
 3000 HPLC system (Dionex, Olten, 
Switzerland) including a SRD-3600 solvent rack, two HPG-3200A binary pumps, an ISO-
3100A isocratic pump, a TCC-3100 thermostatted column compartment with a built-in 10-
port switching valve and a WPS-3000TSL thermostatted plate autosampler set to a 
temperature of 8 °C.  
A schematic representation of the chromatographic set-up is shown in Fig. 1. The prepared 
samples were loaded with a 300 µL/min flow (acetonitrile/water/formic acid, 40/60/0.1; v/v/v) 
onto a trapping column (Mercury Synergy
TM
 4 µm Polar RP 80 Å, 10 x 2.0 mm, Phenomenex, 
Torrance CA, USA) and diluted via a T-union with an aqueous flow containing 0.1% formic 
acid in order to enhance the loading and trapping step efficiencies. After 1 min the valve was 
switched and the trapping column was connected to the analytical column in backflush 
direction. Analytical separation was achieved on a 30 x 2.1 mm column packed with 2.6 µm 
core-shell particles (Kinetex
TM
 PFP 100 Å, Phenomenex, Torrance CA, USA), equipped with 
a guard column (KrudKatcher Ultra, Phenomenex, Torrance CA, USA) and heated to 40 °C. 
Gradient elution of the analytes from the trapping to the analytical column was performed 
with 0.1% formic acid in water as mobile phase A and 0.1% formic acid in acetonitrile as 
mobile phase B. The gradient was raised from 30 to 97.5% B in 1 min and kept isocratic for 
one more minute. Then the valve was switched back to the loading position and both columns 
were re-equilibrated to the initial mobile phase conditions, resulting in a total run time of 4.5 
min. The mobile phase composition and gradient program for each pump are given in detail in 
Table 1.  
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Table 1 Mobile phase composition and gradient conditions for all HPLC pumps 
 
Time 
(min) 
Analytical Column (AC) 
 
Trapping Column (TC) 
Binary Pump 1 
 
Binary Pump 2, Isocratic Pump (IP) 
  % B 
Flow  
(µL/min) 
  Comments   % B 
Flow  
(µL/min) 
Flow IP 
(µL/min) 
  Switching valve 
0.0 30 400  start MS, 
start pumps 
 
40 300 800 
 
TC → waste 
AC → MS 
(loading) 
1.0 30 400  start gradient 
 
40 300 800 
 
TC → AC → 
MS (eluting) 
1.2 →
 
400   
 
40 300 800 
 
 
1.3 400   
 
40 20 20 
 
 
2.0 97.5 400   
 
40 20 20 
 
 
2.9 97.5 400   
 
40 20 20 
 
 
3.0 97.5 400   
 
40 300 800 
 
TC → waste 
AC → MS   
  
3.1 30 400   
 
40 300 800 
 
re-equilibrating 
4.5 30 400   
 
40 300 800 
  
 
Mass spectrometry 
Mass spectrometric data were acquired on a 3200 QTRAP
®
 triple-stage quadrupole mass 
spectrometer (AB SCIEX, Brugg, Switzerland) operated in positive electrospray ionization 
(ESI) and selected reaction monitoring (SRM) mode. The instrument parameters for 
ionization were as follows: ion source voltage, 5250 V; source temperature, 650 °C; curtain 
gas, 25; collision gas, 5; gas 1, 40; and gas 2, 40 (arbitrary units for the gas settings). 
Quadrupole one (Q1) and quadrupole three (Q3) were set to unit resolution. THCCOOH, 
THCCOOH-glucuronide as well as its deuterated analog were measured with two SRM 
transitions each, whereas for THCCOOH-d3 only one transition was monitored. SRM 
conditions were optimized by direct infusion of each analyte and internal standard via syringe 
pump and are specified in Table 2.  
 
Table 2 Optimized MS/MS parameter settings for each of the monitored SRM transitions. 
Bold masses denote quantifier transitions 
Analyte 
Q1 mass  
(m/z) 
Q3 mass  
(m/z) 
Dwell time 
(ms) 
DP (V) EP (V) CE (eV) CXP (V) 
THCCOOH 345.2 327.2 60 40 7 20 4 
 
345.2 299.2 30 40 7 28 4 
THCCOOH-d3 348.2 330.2 30 40 7 20 4 
THCCOOH-glucuronide 521.2 327.2 60 50 4 32 4 
 
521.2 345.2 60 50 4 20 4 
THCCOOH-d3-glucuronide 524.2 330.2 30 50 4 32 4 
  524.2 348.2 30 50 4 20 4 
 
DP, declustering potential; EP, entrance potential; CE, collision energy; CXP, collision cell 
exit potential 
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Data analysis 
Analyst software version 1.5.1 (AB SCIEX, Brugg, Switzerland, 2010) was used for data 
acquisition and processing. Calibration curves were constructed by calculating the peak area 
ratios of analytes to corresponding internal standards for each analyte concentration (x). 
Linear least-squares regression with a 1/x weighting factor was employed for both analytes. 
Bland-Altman  analysis was performed using GraphPad Prism 6.05 for Windows (GraphPad 
Software, La Jolla, CA, USA, 2014). 
 
Validation 
The developed method was validated in terms of linearity, intra- and inter-assay accuracy and 
imprecision, lower limit of quantification (LLOQ), selectivity, extraction efficiency, matrix 
effect, carry-over, dilution integrity, analyte stability and re-injection reproducibility. Method 
validation was performed according to international guidelines on bioanalytical method 
validation [34,35]. 
Linearity of each analyte was determined with seven concentration levels (5, 10, 25, 50, 100, 
250 and 500 µg/L) prepared in duplicate on three different days. Calibration curves were fit 
by unweighted linear least-squares regression and linear least-squares regression employing 
1/x and 1/x
2
 weighting. The calibration models were evaluated based on the percentage 
relative error (%RE) which compares the concentration determined from the regression 
equation with the nominal concentration. The %RE values were plotted versus nominal 
concentration and the sum of absolute %RE values was calculated. The most appropriate 
calibration model was defined as that producing the narrowest distribution of the %RE around 
the concentration axis and the lowest %RE sum across the entire concentration range [36]. 
Calibrators were required to quantify within ± 15% of the target value (± 20% for LLOQ) and 
correlation coefficients (r) should exceed 0.99. 
Accuracy and imprecision of the method were assessed at low, mid and high QC level (15, 
125 and 400 µg/L) as well as at the LLOQ level. Intra-assay accuracy and imprecision were 
determined from six replicates per level in a single run. For the evaluation of the inter-assay 
accuracy and imprecision six replicates of each QC sample were prepared and analyzed on 
three different days (n total = 18). QC concentrations were calculated from freshly prepared 
calibration curves. Accuracy was determined as the percentage of the mean concentration of 
all replicates from the corresponding nominal value. Imprecision was defined as percent 
coefficient of variation (% CV) of the calculated concentrations. The mean concentration at 
each QC level should be within ± 15% of the nominal concentration (± 20% for LLOQ) and 
the imprecision should not exceed 15% CV (20% CV for LLOQ). 
Selectivity was assessed by testing blank blood from six individual sources for the absence of 
signals interfering with the peaks of both analytes and internal standards. In addition, 
selectivity was evaluated by spiking the different blank blood samples to the LLOQ level. 
Interference from endogenous compounds was considered insignificant if any response in the 
blank sample was less than 20% of the LLOQ and 5% of the internal standard response and if 
both analytes in the LLOQ samples quantified within ±20% of the nominal concentrations. 
Matrix effects were examined qualitatively by employing the post-column infusion method. A 
methanolic solution containing the analytes and their internal standards at a concentration of 1 
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µg/mL each was infused at a constant flow rate of 15 µL/min via a T-union into the HPLC 
effluent during the chromatographic analysis of a blank blood extract. The signals of the 
selected ion transitions were examined for any suppression or enhancement over the entire 
chromatographic run. 
Extraction efficiencies were determined at low and high QC concentrations (n = 6 for each 
concentration) and were expressed as the mean cannabinoid peak area of samples spiked 
before protein precipitation divided by the mean peak area of processed blank samples that 
were spiked after protein precipitation. 
Carry-over was assessed in duplicate by injecting a blank sample immediately after the 
highest calibrator. The response in the blank specimen was required to be ≤ 20% of the LLOQ 
and ≤ 5% of the internal standard response to demonstrate absence of carry-over. 
Dilution integrity was evaluated by diluting blood samples fortified with both analytes at two 
concentrations (2500 µg/L and 1000 µg/L, n = 6 each) with blank blood to achieve 1:10 (v/v) 
dilution. Dilution integrity was proven if specimens could be quantified with acceptable 
imprecision (≤ 15% CV) and accuracy (± 15%). 
Matrix stability was only investigated for THCCOOH-glucuronide, since the stability of 
THCCOOH in whole blood under different storage conditions has already been demonstrated 
during validation of our previously developed LC-MS/MS method for the quantification of 
THC, 11-OH-THC and THCCOOH [37]. Stability of THCCOOH-glucuronide was examined 
at low and high QC concentrations under four storage conditions (n = 6 for each concentration 
and condition): two days at room temperature (RT), six days at 4 °C, three months at -20 °C 
and two freeze-thaw cycles (18 h freeze at -20 °C, 6 h thaw at RT). QC working solutions 
containing only THCCOOH-glucuronide were used for preparation of the stability samples. 
After storage, samples were analyzed against a freshly prepared calibration curve and the 
calculated concentrations were compared to the concentrations determined before storage (t = 
0 value). Samples were considered to be stable if their concentrations were within ± 15% of 
the initial values 
Re-injection reproducibility was assessed with six replicates of each QC level. These samples 
were analyzed immediately after sample preparation and were then re-injected after storage at 
4 °C for eight days and quantified against the re-injected calibration curve. Reproducibility 
was acceptable if re-injected samples quantified within ± 15% of the initially measured value. 
 
Application to forensic cases 
The presented method was applied to 926 whole blood specimens which were obtained from 
drivers suspected of DUI and were THCCOOH positive by our routinely used LC-MS/MS 
method [37]. During the time between the routine measurement and the reanalysis with the 
presented method (three to twelve months) the samples were stored at -20 °C. Each LC-
MS/MS run incorporated two calibration curves (one at the beginning and one at the end), QC 
samples at three concentrations, one blank sample, one zero sample (blank blood processed 
with internal standard) and between 38 and 246 unknown samples. The number of QC 
samples was chosen based on the number of unknown samples and amounted to at least 5% of 
the unknowns (or at least two replicates per QC level, whichever number was higher). Using 
two sets of calibration samples per run compensated for any differences in method 
performance that might have occurred across the run. Both sets of calibration samples were 
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used to calculate the calibration curve. At least one of the calibrators at each level was 
required to quantify within ± 15% of the target value and the correlation coefficient r should 
exceed 0.99. Incurred sample reanalysis was performed with a random selection of 60 
samples to verify the reliability and reproducibility of the analyte concentrations in authentic 
samples after storage at -20 °C for three to four months. The difference between the initial 
concentration and the concentration measured during reanalysis should not exceed 20% of 
their mean for at least two-thirds of the repeated samples. 
 
Results and discussion 
Method performance 
We have developed a method for the simultaneous quantification of THCCOOH and 
THCCOOH-glucuronide in whole blood using a column-switching chromatographic approach 
to minimize sample preparation and analytical run time. In recent years, numerous 
publications have demonstrated the great potential of column-switching techniques for the 
analysis of drugs in complex biological matrices [37-41]. The use of a trapping column for 
sample clean-up and concentration and an analytical column for separation and detection 
allowed us to prepare blood samples by a simple protein precipitation step. Since a large 
volume could be injected without compromising the performance of the analytical column, 
sample pre-concentration by evaporation and reconstitution was not necessary. Employing 
two columns each containing a different stationary phase, provided sufficient selectivity to 
obtain excellent separation of the two analytes within only 4.5 min. Average retention times 
were 2.16 min (0.6% CV) for THCCOOH-glucuronide and 2.39 min (0.7% CV) for 
THCCOOH (Fig. 2). The extracted ion chromatogram of THCCOOH also showed a peak at 
2.16 min which corresponded to the THCCOOH fragment originating from in-source decay of 
the glucuronide during the ionization process. Since the two peaks were baseline separated, 
there was no contribution of the in-source decay of THCCOOH-glucuronide to the intrinsic 
amount of free THCCOOH. 
 
Validation 
The method was validated according to the criteria detailed in the Experimental section. 
Inspection of relative percentage errors indicated that linear least-squares regression with a 
1/x weighting factor was the most appropriate calibration model. LLOQ, linearity and 
calibration results are presented in Table 3. The LLOQ, defined as the lowest concentration 
quantifiable with acceptable accuracy (± 20%) and imprecision (≤ 20% CV), was determined 
to be 5 µg/L for both analytes. The accuracy and imprecision results at the LLOQ are 
specified in Table 4. Calibration curves were linear up to 500 µg/L with acceptable 
correlation coefficients r (1/x weighting). The back-calculated concentrations of the 
calibration standards were within ± 8 % of the nominal value. 
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Table 3 Limits of quantification, linear ranges and calibration results (1/x weighting) for the 
determination of THCCOOH and THCCOOH-glucuronide in whole blood by LC-MS/MS 
Analyte 
LLOQ  
(µg/L) 
Linear range 
(µg/L) 
Slope ± SD 
(n = 6) 
y-intercept  ± SD 
(n = 6) 
r ± SD 
(n = 6) 
THCCOOH 5.0 5.0 - 500 0.0057 ± 0.0004 0.0080 ± 0.0072 0.9984 ± 0.0007 
THCCOOH-glucuronide 5.0 5.0 - 500 0.0098 ± 0.0012  -0.0081 ± 0.0081 0.9985 ± 0.0012 
 
Accuracy and imprecision were evaluated at four concentrations across the linear dynamic 
range. The results of these analyses are summarized in Table 4. Both analytes matched the 
validation criteria. Accuracy ranged from 92.0% - 108.0% and imprecision was determined to 
less than 13.5% CV for the two analytes at each QC level. 
 
Table 4 Accuracy and imprecision data. Analyte concentrations of LLOQ, low, mid and high 
QC samples were 5, 15, 125 and 400 µg/L, respectively 
QC level   Intra-assay (n = 6) 
 
Inter-assay (n = 18) 
    
Accuracy 
(%) 
Imprecision 
(% CV) 
  
Accuracy 
(%) 
Imprecision 
(% CV) 
THCCOOH 
     
 
LLOQ 
 
108.0 9.3 
 
104.0 13.5 
 
Low 
 
96.7 5.5 
 
97.3 6.2 
 
Mid 
 
98.6 3.7 
 
97.7 5.5 
 
High 
 
105.5 3.8 
 
102.3 6.6 
        
THCCOOH-glucuronide 
     
 
LLOQ 
 
92.0 4.3 
 
98.0 10.2 
 
Low 
 
93.3 5.0 
 
94.7 6.3 
 
Mid 
 
101.8 3.2 
 
103.4 4.9 
  High   106.0 3.5   104.0 6.3 
 
Selectivity proved to be sufficient. No endogenous interferences were observed for the 
monitored SRM transitions in any of the tested blank blood samples and LLOQ quantification 
was within 18.4% for THCCOOH and 11.6% for THCCOOH-glucuronide, respectively, in all 
six whole blood sources. Extracted ion chromatograms for a blank blood specimen, a blank 
blood specimen spiked with analytes at the LLOQ level and an authentic blood specimen 
from a cannabis consumer are shown in Fig. 2. 
The effect of co-eluting matrix components on the ionization of the analytes was examined 
qualitatively by the post-column infusion technique. Fig. 3 shows the responses obtained after 
injection of an extracted blank blood sample. For both analytes and internal standards an 
abrupt change of the ion intensity was observed between 1.2 – 1.5 min, which was most likely 
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caused by the reduction of the flow rate through the trapping column (Table 1) happening at 
that time. The severe ion suppression effects detected after 2.3 min, however, were most 
probably produced by lipophilic matrix compounds eluting from the column during the 
isocratic hold at 97.5% B at the end of the gradient. After 3.1 min, when the columns were re-
equilibrated, signal intensities gradually returned to their initial value. While no ion 
suppression or enhancement was observed at the retention time of THCCOOH-glucuronide 
and its deuterated analog (2.16 min), the retention time of THCCOOH (2.39 min) coincided 
with the region of ion suppression. The reduced response of THCCOOH was, however, 
compensated for by its internal standard, since their signal suppression profiles were close to 
identical. Thus, quantification was not adversely affected. 
Extraction efficiencies for the analytes and their deuterium-labeled analogs were reproducible 
and reasonably high, ranging from 67.5 – 85.0%. Detailed data are reported in Table 5. 
 
 
Table 5 Extraction efficiency for THCCOOH and THCCOOH-glucuronide from whole 
blood. Analyte concentrations of low and high QC samples were 15 and 400 µg/L, 
respectively 
Analyte 
Extraction efficiency  
(%, n = 6) 
  Low High 
THCCOOH 69.0 69.1 
THCCOOH-d3 67.5 75.2 
THCCOOH-glucuronide 71.9 73.8 
THCCOOH-d3-glucuronide 77.0 85.0 
 
There was no evidence of carry-over for both analytes and their internal standards. Any signal 
present in blank specimens injected after the highest calibration sample was insignificant. 
Dilution integrity was maintained at ten times dilution with blank whole blood. Both analytes 
were quantified within 10.0% of the theoretical concentrations and with an imprecision less 
than 12.2% CV. 
THCCOOH stability in spiked whole blood samples was previously evaluated in our 
laboratory [37]. THCCOOH was stable for 6 h at RT and three freeze-thaw cycles (20 h 
freeze, 4 h thaw at RT). Schwope et al. [25] found that THCCOOH was stable in spiked blood 
for 16 h at RT, 72 h at 4 °C and when subjected to three freeze-thaw cycles (23 h freeze, 1 h 
thaw at RT). Long-term stability of THCCOOH in authentic whole blood samples was 
investigated by Scheidweiler et al. [42] and was reported to be 1 month at 4 °C and 6 months 
at -20 °C. 
Quantification of THCCOOH in THCCOOH-glucuronide stability samples prior to storage 
demonstrated that degradation of the glucuronide during sample processing and injection was 
minimal. Mean percentage of glucuronide hydrolysis was 1.23 ± 0.22% (n = 6). Since pure 
THCCOOH-glucuronide QC solutions were found to contain 0.75 ± 0.05% THCCOOH (n = 
4), glucuronide hydrolysis occurring during extraction was actually even more insignificant.   
THCCOOH-glucuronide was stable under all storage conditions tested (2 days at RT, 6 days 
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at 4 °C, 3 months at -20 °C, two freeze-thaw cycles) with mean concentrations showing less 
than 12.9% deviation from their initial values. Our observations on glucuronide stability are in 
agreement with the findings reported by Schwope et al. [25] and Scheidweiler et al. [42]. 
Re-injection reproducibility met acceptance criteria. Measured concentrations for sample 
extracts after storage at 4 °C for eight days were within 10.2% of the initial values. 
 
Proof of method  
The method was applied to 926 authentic blood samples from a wide variety of cannabis 
consumers. QC samples, which were incorporated in each assay run, were quantified with 
acceptable accuracy and imprecision, thus demonstrating the method’s robustness. Intra- and 
inter-assay accuracy ranged from 87.0 – 113.3% (n = 2 - 8) and 91.7 – 104.9% (n = 32), 
respectively. Intra- and inter-assay imprecision was less than 8.8% CV and 6.6% CV, 
respectively, for the two analytes at each QC level.  
Median concentrations of the authentic blood specimens were 25.7 µg/L for THCCOOH 
(range < 5.0 - 166 µg/L) and 87.1 µg/L (range < 5 – 869 µg/L) for THCCOOH-glucuronide. 
Samples with analyte concentrations exceeding the highest calibration standard were diluted 
with blank blood (1:10) and re-analyzed. 
The vast majority of the samples showed concentrations within the calibration range (92.8% 
for THCCOOH and 99.2% for THCCOOH-glucuronide), indicating that these ranges prove 
useful for analysis of forensic case samples. 
The reliability of the method was further demonstrated by re-analyzing a subset of authentic 
samples, as it is common during incurred sample reanalysis [35]. The percentage difference 
between the original and reanalyzed THCCOOH concentrations was within 20% for 78.3% of 
the repeated samples. For THCCOOH-glucuronide 83.3% of the repeats were within 20%. 
Thus, both analytes met the predetermined criteria. 
Authentic THCCOOH concentrations (n = 926) measured with the presented method were 
compared to those obtained with our previously published, routinely used LC-MS/MS method 
for determination of THC, 11-OH-THC and THCCOOH in whole blood [37]. Bland-Altman 
analysis demonstrated good agreement between the two methods with a bias close to zero (-
0.99 µg/L) and 95% limit of agreement ranging from -12.29 to 10.31 µg/L (calculated as the 
mean difference ± 1.96 SD).  
 
Conclusions 
In this paper, a rapid LC-MS/MS method for the simultaneous analysis of THCCOOH and 
THCCOOH-glucuronide in human whole blood is described. LC-MS/MS enables direct 
quantification of free and glucuronidated THCCOOH avoiding time-intensive sample 
hydrolysis and derivatization, which simplifies result interpretation. The use of column-
switching chromatography with on-line sample enrichment and purification allowed for a 
simple and fast sample preparation procedure and short analytical run time. The method was 
fully validated and proved to be robust, selective, accurate and precise. It was successfully 
used on whole blood samples from a large collective of cannabis consumers, thus proving 
applicable and reliable in the forensic toxicological setting. The method will be employed to 
13 
 
analyze blood samples from a controlled cannabis administration study and will provide 
pharmacokinetic data useful for assessing the suitability of free and glucuronidated 
THCCOOH as indicators of cannabis consumption frequency. In Swiss traffic policy, a 
reliable diagnostic marker for identifying heavy cannabis users is required in the context of 
driving aptitude assessments. 
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Figures 
 
Fig. 1 Schematic representation of the column-switching LC-MS/MS system. a Loading onto 
trapping column and b gradient elution to analytical column. Arrows indicate flow direction 
 
Fig. 2 SRM ion chromatograms of a-b extracted blank whole blood (arrows indicate expected 
retention times), c-d analytes at the lowest calibration level (5 µg/L each), and e-f an 
authentic whole blood specimen from a cannabis consumer (THCCOOH, 97.6 µg/L; 
THCCOOH-glucuronide, 296 µg/L) 
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Fig. 3 Evaluation of matrix effects on a THCCOOH, b THCCOOH-d3, c THCCOOH-
glucuronide and d THCCOOH-d3-glucuronide by post-column infusion following injection of 
an extracted blank blood specimen. Arrows indicate expected retention times 
 
 
